Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest- Additional Information (Detail)

v3.10.0.1
Debt and Interest- Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 12, 2018
Mar. 31, 2018
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Debt [Line Items]          
Payments of Financing Costs     $ 404 $ 1,081  
Opus Credit Facility [Member]          
Debt [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage     12.00%    
Debt instrument Expiration Period Sep. 14, 2019       Sep. 14, 2018
Venture Notes [Member]          
Debt [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage   8.00%      
Debt Instrument, Face Amount   $ 21,700      
Debt Instrument, Term     36 months    
Debt Instrument, Maturity Date, Description     The notes mature 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months.    
NSC [Member] | Venture Notes [Member]          
Debt [Line Items]          
Warrant On Sale Price Of Note Percentage     25.00%    
Payments of Financing Costs   $ 1,700      
Class of Warrant or Right, Expiration Period     10 years    
Aevitas Therapeutics, Inc [Member] | Venture Notes [Member]          
Debt [Line Items]          
Proceeds from Notes Payable     $ 1,800    
Tamid Bio, Inc [Member] | Venture Notes [Member]          
Debt [Line Items]          
Proceeds from Notes Payable     1,100    
Cellvation [Member] | Venture Notes [Member]          
Debt [Line Items]          
Proceeds from Notes Payable     1,000    
Cyprium [Member] | Venture Notes [Member]          
Debt [Line Items]          
Proceeds from Notes Payable     $ 1,200